EXODUS MULTI-DOSE- pyrantel pamoate paste Bimeda Inc.

Approved by FDA under ANADA # 200-350

Exodus® Multi-Dose

(pyrantel pamoate) Paste

Horse Dewormer

Read Entire Carton Carefully Before Using This Product

DESCRIPTION:

Exodus ® Multi-Dose (pyrantel pamoate) Paste is a pale yellow to buff paste containing 43.9% w/w pyrantel pamoate in an inert vehicle. Each syringe contains 7.2 grams pyrantel base in 47.2 grams paste. Each mL contains 171 mg pyrantel base as pyrantel pamoate.

COMPOSITION:

Pyrantel pamoate is a compound belonging to a family classified chemically as tetrahydropyrimidines. It is a yellow, water-insoluble crystalline salt of the tetrahydropyrimidine base and pamoic acid containing 34.7% base activity. The chemical structure and name are given below.

Chemical Name: (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)-vinyl]-pyrimidine 4,4' methylenebis [3-hydroxy-2-naphtholate] (1:1)

INDICATIONS FOR USE:

For the removal and control of mature infections of large strongyles (*Strongylus vulgaris, S. edentatus, S. equinus*); small strongyles; pinworms (*Oxyuris equi*); and large roundworms (*Parascaris equorum*) in horses and ponies.

Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

DOSAGE AND TREATMENT:

Exodus ® Multi-Dose (pyrantel pamoate) Paste is to be administered as a single oral dose of 3 mg pyrantel base per lb of body weight. The syringe has 8 weight mark increments. Each weight mark indicates the recommended dose for 300 lb of body weight. One-half syringe treats a 1200 lb horse.

DOSAGE

Body Weight Range	Volume	e mg Pyrantel Base
up to 300 lb	1/8	900 mg
	syringe	
301 - 600 lb	1/4	1800 mg
	syringe	
601 - 900 lb	3/8	2700 mg
	syringe	
901 - 1200lb	1/2	3600 mg
	syringe	_

Note: Position ring-gauge over appropriate mark on plunger. Each mL contains 171 mg pyrantel base as pyrantel pamoate.

Do not underdose. Ensure each animal receives a complete dose based on a current body weight. Underdosing may result in ineffective treatment, and encourage the development of parasite resistance.

For maximum control of parasitism, it is recommended that foals (2-8 months of age) be dosed every 4 weeks. To minimize the potential source of infection that the mare may pose to the foal, the mare should be treated 1 month prior to anticipated foaling date followed by retreatment 10 days to 2 weeks after birth of foal. Horses and ponies over 8 months of age should be routinely dosed every 6 weeks.

ADMINISTRATION:

After removing the cap, the paste should be deposited on the dorsum of the tongue. Introduce the nozzle end of the syringe at the corner of the mouth. Direct the syringe backwards and depress the plunger to deposit the paste onto the tongue. Given in this manner, it is unlikely that rejection of the paste will occur. Raising the horse's head sometimes assists in the swallowing process. When only part of the paste has been used, replace the cap on the syringe nozzle.

EFFICACY:

Critical (worm count) studies in horses demonstrated that pyrantel pamoate paste administered at the recommended dosage was efficacious against mature infections of *Strongylus vulgaris* (>90%), *S. edentatus* (69%), *S. equinus* (>90%), *Oxyuris equi* (81%), *Parascaris equorum* (>90%), and small strongyles (>90%).

WARNINGS

For oral animal use only. Do not use in horses intended for human consumption.

HUMAN WARNINGS

Keep out of the reach of children.

It is recommended that severely debilitated animals not be treated with this preparation.

OTHER WARNINGS: Parasite resistance may develop to any dewormer, and has been reported for most classes of dewormers. Treatment with a dewormer used in conjunction with parasite management practices appropriate to the geographic area and the animal(s) to be treated may slow the development of parasite resistance. Fecal examinations or other diagnostic tests and parasite management history should be used

to determine if the product is appropriate for the herd prior to the use of any dewormer. Following the use of any dewormer, effectiveness of treatment should be monitored (for example, with the use of a fecal egg count reduction test or another appropriate method). A decrease in a drug's effectiveness over time as calculated by fecal egg count reduction tests may indicate the development of resistance to the dewormer administered. Your parasite management plan should be adjusted accordingly based on regular monitoring.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

RECOMMENDED STORAGE: Store at 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C (59°F-86°F).

ejection of the paste will horse's head sometimes wing process. When only



Net weight: 47.2 g (1.66 oz). Each mL contains 171 mg pyrantel base as pyrantel pamoate.





🕲 Bimeda



oyrantel pamoate) Paste Multi-Dose SD

EXODUS MULTI-DOSE								
pyrantel pamoate paste								
Product Inform	ation							
Product Type		OTC ANIMAL DRUG	Item C	Item Code (Source)		N	NDC:61133-6011	
Route of Administ	ration	ORAL						
Active Ingredient/Active Moiety								
Ingredient Name				Basis of	Streng	gth	Strength	
PYRANTEL PAMOATE (UNII: 81BK194Z5M) (PYRANTEL - UNII:4QIH0N49E7)			9E7)	PYRANTEL			7.2 g in 47.2 g	
Packaging								
# Item Code	Packa	ge Description	Marketing Start Date		Marketing End Date		g End Date	
1 NDC:61133-6011-1	47.2 g in	1 SYRINGE						
Marketing Information								
Marketing Category	Applica	ation Number or Monograph Citation		Marketing Start Date		tart	Marketing End Date	
ANADA	ANADA2003	50		03/25	/2003			

Labeler - Bimeda Inc. (060492923)

Registrant - Bimeda Inc. (060492923)

Establishment								
Name	Address	ID/FEI	Business Operations					
Bimeda-MTC Animal Health		256232216	manufacture					

Revised: 12/2023

Bimeda Inc.